-$0.02 EPS Expected for Cardiovascular Systems Inc (CSII) This Quarter

Analysts predict that Cardiovascular Systems Inc (NASDAQ:CSII) will report earnings of ($0.02) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Cardiovascular Systems’ earnings. The lowest EPS estimate is ($0.03) and the highest is ($0.01). Cardiovascular Systems posted earnings per share of $0.03 in the same quarter last year, which suggests a negative year-over-year growth rate of 166.7%. The business is expected to issue its next earnings results on Wednesday, May 2nd.

On average, analysts expect that Cardiovascular Systems will report full-year earnings of ($0.07) per share for the current year, with EPS estimates ranging from ($0.08) to ($0.04). For the next financial year, analysts forecast that the business will report earnings of $0.10 per share, with EPS estimates ranging from ($0.09) to $0.28. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Cardiovascular Systems.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.51%. The business had revenue of $52.63 million for the quarter, compared to analysts’ expectations of $53.39 million. During the same period in the prior year, the firm earned $0.03 earnings per share. Cardiovascular Systems’s revenue was up 5.2% compared to the same quarter last year.

CSII has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $36.00 price target (down from $37.00) on shares of Cardiovascular Systems in a research note on Thursday, October 26th. Zacks Investment Research raised shares of Cardiovascular Systems from a “sell” rating to a “hold” rating in a research note on Monday, November 13th. Raymond James Financial reissued a “hold” rating on shares of Cardiovascular Systems in a research note on Monday, December 4th. William Blair reissued a “market perform” rating on shares of Cardiovascular Systems in a research note on Thursday, December 21st. Finally, BidaskClub cut shares of Cardiovascular Systems from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 27th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $27.00.

A number of hedge funds have recently made changes to their positions in CSII. Champlain Investment Partners LLC boosted its stake in Cardiovascular Systems by 21.3% in the fourth quarter. Champlain Investment Partners LLC now owns 2,253,355 shares of the medical device company’s stock valued at $53,382,000 after acquiring an additional 396,145 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Cardiovascular Systems by 69.7% in the fourth quarter. Renaissance Technologies LLC now owns 899,300 shares of the medical device company’s stock valued at $21,304,000 after acquiring an additional 369,500 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Cardiovascular Systems by 132.7% in the third quarter. Point72 Asset Management L.P. now owns 469,978 shares of the medical device company’s stock valued at $13,230,000 after acquiring an additional 267,988 shares during the last quarter. Vanguard Group Inc. boosted its stake in Cardiovascular Systems by 12.6% in the second quarter. Vanguard Group Inc. now owns 1,864,604 shares of the medical device company’s stock valued at $60,096,000 after acquiring an additional 208,248 shares during the last quarter. Finally, Gabelli Funds LLC boosted its stake in Cardiovascular Systems by 223.1% in the third quarter. Gabelli Funds LLC now owns 218,500 shares of the medical device company’s stock valued at $6,151,000 after acquiring an additional 150,880 shares during the last quarter. 74.22% of the stock is currently owned by hedge funds and other institutional investors.

Cardiovascular Systems (CSII) traded down $0.99 on Tuesday, hitting $21.85. 823,084 shares of the stock traded hands, compared to its average volume of 311,396. Cardiovascular Systems has a twelve month low of $21.03 and a twelve month high of $33.11. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.30 and a quick ratio of 3.83. The company has a market capitalization of $744.09, a PE ratio of -218.48 and a beta of 2.32.

COPYRIGHT VIOLATION NOTICE: “-$0.02 EPS Expected for Cardiovascular Systems Inc (CSII) This Quarter” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/13/0-02-eps-expected-for-cardiovascular-systems-inc-csii-this-quarter.html.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Get a free copy of the Zacks research report on Cardiovascular Systems (CSII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply